This technology describes a process of electropsinning using FDA Q3C Class 3 solvents and polymer blends to provide less toxic electrospun fibers.
Electrospinning fibers is an established fabrication method for multiple applications in which a polymer is dissolved into a solvent, loaded into syringe, and exerted out through the syringe tip after electrostatic forces are applied. Traditional methods of electrospinning are performed using “harsh” solvents that are typically categorized as Class 2 solvents under FDA’s “Q3C Guidance for Industry.” However, a safer alternative electrospinning method is necessary for human applications, since these Class 2 solvents are limited in pharmaceutical products due to their inherent toxicities.
This technology describes a process of electrospinning using acetic acid, a safer Class 3 solvent, and a blend of poly(lactic-co-glycolic) acid (PLGA) and poly(-caprolactone) (PCL) as the polymers. The resulting fibers have also successfully incorporated ceramics, like calcium deficient apatite, and growth factors, such as insulin-like growth factor 1, which demonstrates versatile fiber composition for multiple applications. This “green” electrospinning method serves as a potential fabrication method for less toxic and risk averse human bone, cartilage, and tissue repairs, with further applications in textiles.
This technology used to fabricate a neocartilage matrix that was comparable to native and grafted cartilage when tested in an osteochondral explant model in vivo.
Patent Pending
IR CU19028
Licensing Contact: Joan Martinez